IKT
Inhibikase TherapeuticsDNasdaq / Pharmaceuticals, Biotechnology & Life Sciences
Last Price
At close
2026-07-18
Current thesis
First-patient enrollment in IMPROVE-PAH confirms the program has moved from planning into execution, and the 10-K shows $178.8 million of cash, cash equivalents, and marketable securities with management stating this funds normal operations for at least twelve months from the March 26, 2026 filing date [#8-K-2026-04-07] [#10-K-2026-03-26]. At roughly a $243 million market cap, that leaves a relatively modest enterprise value for a single-asset Phase 3 PAH story if enrollment and safety hold up.
Posture
Defensive
Lead driver
Momentum
What changed
Momentum remains the lead driver in the composite.
What can break
Additional capital may be required before full value realization despite current cash runway
Momentum
84
Value
41
Sentiment
29
Setup hits (3d)
— · Net —
AI TargetsBase $1.50 · Bull $3.40 · Bear $0.70
Data freshness
Prices
As of 2026-07-18
Fundamentals
As of 2026-07-17 • Vendor: Data Vendor v1
Scores
As of 2026-07-18 • Model: HYBRID_IC_RP
AI Memo
As of 2026-04-15 • Model: RankAlpha Sentiment Codex
Investment thesisAs of 2026-07-18
Investment thesis
As of 2026-07-18
Supporting evidence
What
Grade D · Defensive
Confidence Medium · Net —
Target $6.00
Why
Momentum84 · Δ7d -
Value41 · Δ7d -0.1
Sentiment29 · Δ7d -
So what
Weak posture. Prioritize risk control and patience.
Lead driver: Momentum · See technicals
Momentum
84
26% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Value
41
39% active weight
Current posture
7d trendFlat
Δ7d
-0.1
Δ21d
0.0
Sentiment
29
34% active weight
Current posture
7d trendTrend unavailable
Trend unavailable
Δ7d
-
Δ21d
-
Why this grade
Composite grade D. Momentum 84.3 / Value 41.1 / Sentiment 28.6
Fundamentals (TTM)As of 2026-07-17
Fundamentals (TTM)
As of 2026-07-17
Market Cap
$278.59M
Beta
0.84
Shares Out
132.03M
P/E (TTM) · Derived
-4.3
P/S (TTM)
-
P/FCF (TTM) · Derived
-6.88
Rev YoY
-100.0%
EPS YoY
-37.8%
Gross Margin
+67.0%
Op Margin
-23885.1%
Net Debt
-$178.76M
Current Ratio
30.14
As of 2026-07-18 • Updated nightlySource: Internal modelMethodology